Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3SBioSTU:83B +1.50%89 Receivables Turnover is 11.03 as of Dec. 2025. GuruFocus rates STU:83B with a GF Score™ of 89/100 and a GF Value™ of €1.41 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 840 Biotechnology companies, 3SBio ranks better than 87.62% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. 3SBio's Revenue for the
six
months ended in Dec. 2025 was €1,618 Mil. 3SBio's average Accounts Receivable for the
six
months ended in Dec. 2025 was €147 Mil.
Hence, 3SBio's Receivables Turnover for the
six
months ended in Dec. 2025 was 11.03.
3SBio (STU:83B) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
3SBio Receivables Turnover Related Terms
3SBio Receivables Turnover Historical Data
* Premium members only.
The historical data trend for 3SBio's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:83B vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, 3SBio's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
3SBio Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 3SBio's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where 3SBio's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
3SBio (STU:83B) has a Receivables Turnover of 11.03 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on 3SBio and its competitors. According to the industry distribution chart, 3SBio ranks #104 out of 840 companies in the Biotechnology industry, placing it in the top 12.4%.
Is 3SBio's Receivables Turnover too high?
3SBio's current Receivables Turnover is 11.03. The Biotechnology industry median Receivables Turnover is 5.28. 3SBio's value of 11.03 is 109.1% above this industry median. Based on the distribution chart, 3SBio ranks #104 out of 840 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, 3SBio has a GF Score™ of 89/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 3SBio's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 3SBio ranks #104 out of 840 companies for Receivables Turnover. This places 3SBio in the top 12% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.28. 3SBio's value of 11.03 is 109.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 3SBio's current Receivables Turnover of 11.03 is 109.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on 3SBio and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 3SBio's current Receivables Turnover is 11.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3SBio stock overvalued right now?
Based on GuruFocus' analysis, 3SBio (STU:83B) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.41, compared to a current price of €1.87 — trading 32.6% above its estimated fair value. The current Receivables Turnover is 11.03 and 109.1% above the Biotechnology industry median of 5.28. 3SBio's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For 3SBio (STU:83B), the current Receivables Turnover is 11.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 3SBio (STU:83B) Overvalued in 2026?
Based on GuruFocus' analysis, 3SBio stock appears to be overvalued.
The current stock price of €1.87 is trading 32.6% above its estimated GF Value™ of €1.41.
GuruFocus considers 3SBio to be Significantly Overvalued.
Key valuation signals for STU:83B:
Receivables Turnover: 11.03
GF Value™: €1.41 vs. price of €1.87 (32.6% above fair value)
Industry Position: 109.1% above the Biotechnology median (#104 of 840)
No single metric tells the full story. See the STU:83B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
3SBio Inc is an investment holding company. It is a primary biotechnology company. The company is principally engaged in the development, production, marketing and sale of biopharmaceutical products in the People's Republic of China. The group has only one operating segment. It has presence in Chinese mainland, USA, Other countries/regions. The majority of revenue comes from USA. The core commercialized products of the group include several bio-pharmaceutical drugs, namely, TPIAO, recombinant human erythropoietin (rhEPO) products EPIAO and SEPO, Yisaipu and Cipterbin, and a small molecule drug, Mandi series of minoxidil drugs.
89GF Score
Get the complete analysis for STU:83B
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:83B has been successfully added to your 
